Eli Lilly and Company: Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

Press/Media

Period	2 Jul 2024

Media coverage

Title	Eli Lilly and Company: Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Media name/outlet	FinanzNachrichten.de
Country/Territory	Germany
Date	2/07/24
URL	ct.moreover.com/?a=54205079412&p=1gw&v=1&x=KKWW3sAapeFKM6VmcTlEjw
Persons	Howard Fillit